AZD2932inhibitor of VEGFR-2, PDGFRβ, Flt-3, and c-Kit CAS# 883986-34-3 |
- MK-4827
Catalog No.:BCC1761
CAS No.:1038915-60-4
- BMN-673 8R,9S
Catalog No.:BCC1422
CAS No.:1207456-00-5
- XAV-939
Catalog No.:BCC1120
CAS No.:284028-89-3
- PJ34
Catalog No.:BCC1865
CAS No.:344458-19-1
- ABT-888 (Veliparib)
Catalog No.:BCC1267
CAS No.:912444-00-9
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 883986-34-3 | SDF | Download SDF |
| PubChem ID | 11517980 | Appearance | Powder |
| Formula | C24H25N5O4 | M.Wt | 447.49 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 41 mg/mL (91.62 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 2-[4-(6,7-dimethoxyquinazolin-4-yl)oxyphenyl]-N-(1-propan-2-ylpyrazol-4-yl)acetamide | ||
| SMILES | CC(C)N1C=C(C=N1)NC(=O)CC2=CC=C(C=C2)OC3=NC=NC4=CC(=C(C=C43)OC)OC | ||
| Standard InChIKey | TWYCZJMOEMMCGC-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C24H25N5O4/c1-15(2)29-13-17(12-27-29)28-23(30)9-16-5-7-18(8-6-16)33-24-19-10-21(31-3)22(32-4)11-20(19)25-14-26-24/h5-8,10-15H,9H2,1-4H3,(H,28,30) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | AZD2932 is a potent and multi-targeted kinase inhibitor VEGFR2, PDGFβ, Flt-3 and c-Kit with IC50s of 8, 4, 7 and 9 nM in cell assay, respectively.In Vitro:AZD2932 has a potent and balanced profile against PDGFβ, VEGFR-2, Flt-3 and c-Kit. It does not inhibit the various cytochrome P450 isoforms with the worst IC50 being against 2C9 (8.0 μM). AZD2932 has no activity against hERG (IC50=137 μM)[1].In Vivo:Twice daily oral dosing (b.i.d.) of AZD2932 10 h apart results in significant tumor growth inhibition of 64% for both 50 and 12.5 mg/kg doses on the day the control animals are terminated. Xenografts bearing non PDGFβ expressing tumor cells are also sensitive to AZD2932 treatment: growth of Calu-6 tumor is inhibited by 81% and 72% at 50 and 12.5 mg/kg b.i.d. and and LoVo tumors by 67% at 50 mg/kg b.i.d. This is due AZD2932 potent activity against VEGFR2 as well as a potential effect on pericytes and tumor-associated fibroblasts due to PDGFR a and b inhibition. AZD2932 at 3–50 mg/kg b.i.d. 10 h apart gives 60–80% inhibition of both p-VEGFR2 and p-PDGFβ in a 1:1 ratio[1]. References: | |||||
Animal Administration
[1]
Mice: To confirm that AZD2932 has similar potency against both PDGFβ and VEGFR-2 phosphorylation, the female nude mice bearing C6 tumors are dosed iv with VEGF-A and PDGFBB 5 min prior to cull and 6 h post last dose of AZD2932 and the lungs excised immediately after. Lung lysates are analyzed by western blot for total and phosphorylated VEGFR-2 and PDGFβ[1].
References:
[1]. Plé PA, et al. Discovery of AZD2932, a new Quinazoline Ether Inhibitor with high affinity for VEGFR-2 and PDGFR tyrosine kinases. Bioorg Med Chem Lett. 2012 Jan 1;22(1):262-6.
AZD2932 Dilution Calculator
AZD2932 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.2347 mL | 11.1734 mL | 22.3469 mL | 44.6937 mL | 55.8672 mL |
| 5 mM | 0.4469 mL | 2.2347 mL | 4.4694 mL | 8.9387 mL | 11.1734 mL |
| 10 mM | 0.2235 mL | 1.1173 mL | 2.2347 mL | 4.4694 mL | 5.5867 mL |
| 50 mM | 0.0447 mL | 0.2235 mL | 0.4469 mL | 0.8939 mL | 1.1173 mL |
| 100 mM | 0.0223 mL | 0.1117 mL | 0.2235 mL | 0.4469 mL | 0.5587 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
AZD2932 is a potent inhibitor for multiple protein tyrosine kinases (IC50 = 8 nM, 4 nM, 7 nM, and 9 nM for VEGFR-2, PDGFRβ, Flt-3, and c-Kit, respectively.) [1]
VEGFR are receptors for vascular endothelial growth factor and belong to receptor tyrosine kinases. It mediates in various cellular functions, including endothelial proliferation, migration, survival, tubular morphogenesis and sprouting. PDGFR are platelet-derived growth factor receptors that exhibit intracellular tyrosine kinase activity. It involves in embryonic development, angiogenesis, proliferation and differentiation etc.
AZD2932 has a potent and balanced profile against PDGFR, VEGFR-2, Flt-3 and c-Kit (IC50: 0.009). It also has a good fraction unbound between 3.3% free in human and 7.0% in dog sera and has no activity against hERG. [1]
In female nude mice bearing C6 tumors, AZD2932 treatment at 3–50 mg/kg b.i.d. 10 h apart give 60–80% inhibition of both p-VEGFR-2 and p-PDGFRb in a 1:1 ratio. [1]
Reference:
1. Plé PA, Jung F, Ashton S, Hennequin L et al. Discovery of AZD2932, a new Quinazoline Ether Inhibitor with high affinity for VEGFR-2 and PDGFR tyrosine kinases. Bioorg Med Chem Lett. 2012 Jan 1;22(1):262-6.
- 8alpha-(2-Methylacryloyloxy)-1-O-methylhirsutinolide 13-O-acetate
Catalog No.:BCN7106
CAS No.:883872-71-7
- 8-Lavandulylkaempferol
Catalog No.:BCN3961
CAS No.:883859-83-4
- Adrenorphin
Catalog No.:BCC1021
CAS No.:88377-68-8
- DPDPE
Catalog No.:BCC5758
CAS No.:88373-73-3
- (9Z,12Z)-N-(3-Methoxybenzyl)octadeca-9,12-dienamide
Catalog No.:BCN1316
CAS No.:883715-22-8
- N-Benzyloleamide
Catalog No.:BCN1317
CAS No.:101762-87-2
- N-Benzyllinolenamide
Catalog No.:BCN6531
CAS No.:883715-18-2
- E 64d
Catalog No.:BCC1127
CAS No.:88321-09-9
- BI 78D3
Catalog No.:BCC8089
CAS No.:883065-90-5
- CCG 50014
Catalog No.:BCC4897
CAS No.:883050-24-6
- HC 067047
Catalog No.:BCC7861
CAS No.:883031-03-6
- Polygalasaponin F
Catalog No.:BCN2317
CAS No.:882664-74-6
- Methyl syringate
Catalog No.:BCN4430
CAS No.:884-35-5
- L-(-)-α-Methyldopa hydrochloride
Catalog No.:BCC4083
CAS No.:884-39-9
- 6,7-Dihydroxycoumarin-4-Acetic Acid
Catalog No.:BCC9205
CAS No.:88404-14-2
- Buparvaquone
Catalog No.:BCC5437
CAS No.:88426-33-9
- (E)-FeCP-oxindole
Catalog No.:BCC6078
CAS No.:884338-18-5
- Murraxocin
Catalog No.:BCN4431
CAS No.:88478-44-8
- Artesunate
Catalog No.:BCN2457
CAS No.:88495-63-0
- Manassantin A
Catalog No.:BCC8207
CAS No.:88497-87-4
- Farrerol 7-O-glucoside
Catalog No.:BCN6412
CAS No.:885044-12-2
- Benzotetramisole
Catalog No.:BCC8861
CAS No.:885051-07-0
- ARRY-520 R enantiomer
Catalog No.:BCC1368
CAS No.:885060-08-2
- ARRY 520 trifluoroacetate
Catalog No.:BCC2391
CAS No.:885060-09-3
Discovery of AZD2932, a new Quinazoline Ether Inhibitor with high affinity for VEGFR-2 and PDGFR tyrosine kinases.[Pubmed:22153662]
Bioorg Med Chem Lett. 2012 Jan 1;22(1):262-6.
A new series of Quinazoline Ether Inhibitor which potently inhibits VEGFR-2 and PDGFR tyrosine kinases is described here. In vitro, pharmacokinetics and in vivo evaluations led to the selection of AZD2932.
